The Medicines and Healthcare products Regulatory Agency (MHRA) began a review of safety data for the class of drugs, known as GLP-1 receptor agonists, more than a year ago after some patients reported suicidal or self-harming thoughts.
from Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/pdEn0BO
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment